Subscribe By RSS
Bristol-Myers Squibb (BMY) - Bull Of The Day
By Zacks Investment Research on August 17, 2009 | More Posts By Zacks Investment Research | Author's Website
Bristol-Myers Squibb (BMY) reported second quarter earnings of 56 cents per share, which beat the Zacks Consensus Estimate of 47 cents. Mega-blockbuster Plavix should continue driving growth at Bristol-Myers.
However, patent expirations loom large on Bristol starting 2011 when the Plavix patent expires. In order to compensate for the loss in revenues when Plavix loses exclusivity, Bristol-Myers is working on bringing new products to market.
Additionally, management is working hard to reduce costs and shed less profitable and non-core businesses. We believe the company could be an attractive takeover candidate for a larger pharma name such as Sanofi-Aventis or AstraZeneca.
We have an Outperform rating on the stock with a price target of $25.
Subscribe by RSS 
Subscribe by Email
Email This Post To A Friend
Silver ETFs: More Gains To Come? 
Here’s A Sector To Short - Protect Yourself Against An Imminent Stock Market Correction
- Oil Seems Like It’s Going Nowhere… But The Story Is Very Different Below The Surface
- Insider Selling Can Be An Important Tool In Determining Potential Trouble For Both Individual Stocks And The Broader Market
- BoJ Raises Economic View - 34 mins ago
- South Korea’s Tourist Arrivals Hit Record High - 44 mins ago
- Indian Market Slips After 2-day Rally - 48 mins ago
- India’s Services Sector Attracts Highest FDI During April-August - 1 hr ago
- Japan’s FinMin: Fiscal Spending In Japan Cannot Help Tackle Weak Demand - 1 hr ago
